Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > No value for Pipeline

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Jan 16, 2021 2:23pm

155 Views

Post# 32313696

RE:RE:RE:RE:RE:No value for Pipeline

The momentum was Halted !!!! WHY?

scarlet1967 wrote: They said they got the letter to go a head with NASH phase 3 but need to adjust the protocol so I am not sure why we still put probability rate on it.
Even if the EMA's approval is questionable that alone shouldn't rush them to close a low ball deal as the whole NASH was questionable just before the good PR.
The good PR stated record sales when nobody would bet on it, many questioned company's ability to run two trials at the same time well they start the oncology in March and projected to start the NASH with or without Europe in Q3 just few months later.
I think the PR even without Europe was overall very good so they should let the market absorb the news and promote the good news followed by decent SP appreciation before pull the trigger on the dilution.
They just got it all wrong, even if NASH Europe is a no go the overall progress was very good it's either the company incorrectly anticipated a bad reaction to the good PR or a very conservative board didn't have the stomach to wait.
Again just 10 days ago we didn't even know whether they have submitted any of the protocols and the NASH as per some posters would have no chance for straight phase 3!!!